Nobel laureate David Baltimore throws his weight behind I/O startup looking to craft off-the-shelf CAR therapies
In the insular world of biotech, names matter — and no names shine brighter than those luminaries with a Nobel Prize on their record. Now, a Los Angeles startup working at the furthest frontiers of cell therapeutics is standing on the shoulders of a laureate of its own and looking to rewrite the fight against solid tumors.
On Tuesday, Appia Bio launched with $52 million in Series A financing led by 8VC and a platform focused on what are called invariant natural killer T cells (iNKT), an extremely rare immune cell the biotech hopes to reengineer to bust malignant tumors through a “best of both worlds” attack plan, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.